Short answer
Bristol Myers Squibb (BMY) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Bristol-Myers Squibb reported third-quarter 2026 financial results.
Bristol Myers Squibb 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Bristol-Myers Squibb reported third-quarter 2026 financial results
- Earnings Press Release furnished as Exhibit 99.1, containing the detailed financial results and management commentary
Item 7.01 · Regulation FD Disclosure
- Bristol Myers posted a presentation covering financial and operating initiatives for its third-quarter 2026 results webcast
- Materials support investor review of management’s Q3 2026 outlook, performance commentary and strategic priorities
- Presentation includes non-GAAP measures, with GAAP reconciliations and explanations in the earnings press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $13.1B, up 7%, led by Growth Portfolio revenue of $7.7B, up 12%
- GAAP EPS $1.05 and non-GAAP EPS $1.35, each including a $(0.58) Acquired IPRD and licensing impact
- 2026 revenue guidance raised to $49.75B-$50.25B, signaling continued portfolio momentum
- 2026 non-GAAP EPS lowered to $6.35-$6.55, including a $(0.60) Acquired IPRD and licensing impact
- Gross margin fell to 68.3% from 71.9%, reflecting product mix and a one-time contract termination charge
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $13.1B, up 7% year over year, with Growth Portfolio revenue $7.7B, up 12%
- Growth led by Eliquis $4.69B, up 25%, plus Camzyos $420M, up 42%, and Breyanzi $526M, up 46%
- GAAP diluted EPS $1.05 versus $1.08, pressured by acquired IPR&D charges of $1.6B
- October guidance raised revenue to $49.75B-$50.25B, but diluted EPS reduced to $6.35-$6.55 from $6.75-$7.00
- Cash ~$13.0B, debt ~$42.9B, and ~$5B remaining share-repurchase authorization support continued capital returns and business development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bristol Myers Squibb 8-K filings
Get the next BMY 8-K as it lands
Follow BMY for push alerts, or ask the research agent what this filing means.